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Abstract 
 
Despite its toxicity, botulinum neurotoxin type A (BTX-A) is a valuable therapeutic agent for 
several motor, autonomic and pain disorders. Numerous studies have described its peripheral 
as well as central effects. Using reversed-phase High Performance Liquid Chromatography 
with Electrochemical Detection (HPLC-ED) and gradient elution, we quantified the 
concentrations of dopamine (DA), noradrenaline (NA), serotonin (5-HT) and their metabolites 
in 10 brain regions, ipsilateral and contralateral from the site of unilateral BTX-A 
administration (5 U/kg) into the rat whisker pad. In regions associated with nociception and 
pain processing we also examined possible BTX-A effects in combination with formalin-
induced inflammatory orofacial pain. The dominant BTX-A effects on the monoamines and 
their metabolites were insignificant. The only significant increase caused by BTX-A alone 
was that of NA in striatum and serotonin in hypothalamus. While antinociceptive effects of 
BTX-A are most probably not related to central monoamine concentrations, the localized 
increased NA and 5-HT concentrations might play a role in reported BTX-A efficacy for the 
treatment of depression.  
 
Keywords: Botulinum neurotoxin type A, monoamines, pain, depression, High Performance 
Liquid Chromatography with Electrochemical Detection 
 
Highlights 
• Effects of Botulinum toxin A (BTX-A) on central monoamines and their metabolites were 
analyzed. 
• Antinociceptive effects of BTX-A are most probably not related to central monoamine 
concentrations. 
• Monoamine hypothesis: low levels of serotonin (5-HT), noradrenaline (NA) and/or 
dopamine (DA) linked to depression. 
• Observed increased NA and 5-HT concentrations might play a role in BTX-A efficacy for 
treatment of depression. 
• Changes in neurotransmission by BTX may be able to influence depression, sleep and pain. 
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1. INTRODUCTION 
 
Botulinum neurotoxins (BTX), produced by anaerobic bacteria of the genus Clostridium 
(Clostridium. botulinum, Clostridium. barati, Clostridium argentinense), are the most potent 
toxins known [40]. Despite the toxicity, Botulinum neurotoxin type A (BTX-A) local 
application in small doses is proven to be effective for numerous clinical conditions such as 
dystonias, spasms, strabismus, bruxism, hyperhydrosis, overactive bladder, gastroparesis, 
migraine and musculoskeletal pain [11]. Structurally, BTX consist of a heavy and a light 
chain linked by a disulphide bond and non-covalent interactions. The carboxy-terminus of the 
heavy chain binds with extraordinary affinity and specificity to nerve terminals [6]. Although 
differing in clinical manifestation, the fundamental mode of action – inhibition of 
neurotransmission – is common to all Clostridium neurotoxins [5,33,44]. In vitro and in vivo 
animal studies show that BTX alters acetylcholine, glutamate, noradrenaline, serotonin, 
dopamine, and glycine transmission, and may change the electrophysiologic properties, 
differentiation, and survival of central neurons [10]. Inhibition of neurotransmitter release by 
BTX is caused by the specific cleavage of a group of proteins integral to the exocytotic 
process, the SNARE proteins (soluble NSF-attachment protein receptors). The light chain 
plays a major role in that step, acting as a Zn
2+
-dependent endopeptidase. Cleavage of one or 
more of the SNARE proteins leads to a block in the release of vesicular contents to the 
extracellular environment [44]. Along with the well known peripheral effects, preclinical and 
clinical studies have provided evidence for central effects of BTX-A mediated by toxin axonal 
transport to CNS [2, 3, 6, 26, 27]. The aim of this study was to investigate possible changes of 
concentrations of neurotransmitters and their metabolites in sensory, limbic and motor brain 
regions after facial administration of BTX-A in rats.  
 
 
2. MATERIALS AND METHODS 
 
2.1. Animals 
Male Wistar rats (University of Zagreb School of Medicine, Croatia), weighing 300-400 g, 
kept on 12 h/12h light and dark cycle, were used in all experiments. The experiments were 
conducted according to the European Communities Council Directive (86/609/EEC), the 
Croatian Law on Animal Protection (Zakon o zaštiti životinja NN 135/06), 
and recommendations of the International Association for the Study of Pain by Zmmermann 
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[51]. All efforts were made to reduce the number of animals used and to reduce their 
suffering. Brain regions were analyzed from either two or four differently treated groups of 
rats, each group containing a total of 10 rats. Animal procedures were approved by the 
institutional review board of the University of Zagreb School of Medicine (permit No. 07-
76/2005-43). 
 
2.2. BTX-A injections  
Conscious, restrained rats were injected unilaterally with 20 μl of saline-diluted BTX-A 
therapeutic preparation (Botox®, INN: Clostridium botulinum type A neurotoxin complex, 
Allergan Inc., Irvine, CA, USA) using a 27 1/2-gauge needle into the whisker pad. 1 unit (1 
U) of BTX-A preparation contains 48 pg of 900 kDaBoNT/A complex. 5 U/kg dose was 
chosen based on previous experiments [28]. 
 
2.3. Behavioral testing 
The effect of BTX-A was assessed in a model of formalin-induced orofacial pain 7 days post 
peripheral toxin injection. Prior to behavioral measurement, the rats were allowed to 
accommodate to testing cage environment. The rats were then briefly restrained and injected 
with 50 μl of saline-diluted 2.5% formalin (0.92 % formaldehyde, Formalin, Kemika, Zagreb, 
Croatia) into the whisker pad ipsilateral to BTX-A pretreatment and returned to cages for 
observation period of 45 min. The number of seconds of formalin-induced ipsilateral facial 
rubbing/grooming was measured in 3 min periods during phases I and II of formalin-induced 
pain [36]. Phase I (0-12 min) behavior represents the immediate pain response characterized 
by direct chemical stimulation of peripheral nerve endings with formalin.  Phase II (12-45 
min) behavior is characterized by delayed hyperalgesic response maintained by ongoing 
afferent input and central sensitization. 
 
Brain region tissue preparation 
One hour after formalin injection, the animals were deeply anesthetised (chloralhydrate, 
Sigma, St Louis, USA; 300 mg/kg i.p.), the brain tissue was quickly excised and immersed 
into the liquid nitrogen. The brain tissue was then kept on -80°C. Prior to homogenization, the 
frozen brainstem was placed to cryostat-cooled environment (-25°C) for dissection of 
multiple ipsilateral and contralateral regions without thawing. The brain was carefully 
sectioned into thick coronal sections (~3 mm) by using a microtome knife blade, and the 
outlines of different regions were identified visually using the rat stereotaxic atlas by Paxinos 
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and Watson, and appropriate landmarks for each region (central canal, obex, aqueduct, 
ventricles, etc.). The nuclei were excised manually using pre-cooled scalpel and forceps. 
Dissected tissue was then kept on -80 °C until homogenization. 
 
2.5. HPLC analysis 
 
2.5.1. Chemicals  
Noradrenaline (NA), 3-methoxy-4-hydroxyphenylglycol (MHPG), dopamine (DA), 
homovanillic acid (HVA), 5-hydroxytryptamine (serotonin, 5-HT), 5-hydroxyindoleacetic 
acid (5-HIAA), triethylamine (TEA), ethylene-diamine-tetra-acetic acid (EDTA), 1-
octanesulfonic acid (OSA), 3,4-dihydroxyphenylacetic acid (DOPAC), trisodium salt of 
calcium diethylenetriaminepentaacetate (DTPA) and methanol Chromasolv
®
 were purchased 
from Sigma-Aldrich, Steinheim, Germany; sodium dihydydrogen phosphate monohydrate 
(NaH2PO4 • H2O) and phosphoric acid (H3PO4) from Merck, Darmstadt, Germany; sodium 
hydroxide from AppliChem, Darmstadt, Germany. Ultrapure water was produced in-house 
using a Barnstead NANOpure
®
 Diamond
™
 system (Thermo Fisher Scientific, Essex, UK). All 
chemicals were of puriss p.a. grade. 
 
2.5.2. Preparation of samples 
First, 15 - 25 mg of tissue of the region of interest was weighed and transfered into 5 ml tubes 
[scale: „Feinwaage HL52" (Mettler-Toledo GmbH, Gießen, Germany); tubes: Polypropylen-
Zentrifugenröhrchen 5 ml, 75 x 12 mm, REF 55.526 (Sarstedt AG & Co., Nümbrecht, 
Germany)]. The tissue was kept frozen on dry ice as far as possible to prevent post mortem 
changes. The tissue was sonicated [sonicator: „Ultraschallhomogenisator Branson Digital 
Sonifier" (G. Heinemann Ultraschall- und Labortechnik, Schwäbisch-Gmünd, Germany)] in 
1 : 10 to 1:50 dilution within an aqueous solution of H3PO4 (150 mM) and DTPA (500 µM) 
on ice under argon atmosphere. The inert gas argon was applied to oust oxygen from the tube 
during sonication to prevent analytes’ degradation by oxidation. An amplitude of 15 % was 
used and sonication was performed until the tissue was visibly homogenised. Homogenates 
were centrifuged (20 min; 4-8 °C; 40700 g). Supernatants were transferred into 
1.5 ml-reaction tubes and stored at -80 °C until analysis. Prior to analysis, thawed 
homogenates were filtered via microcentrifugal filters (membrane of regenerated cellulose; 
pore size 0.2 µm; Amchro GmbH, Hattersheim, Germany; 6 min, room temperature, 21400 
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g). For analysis the filtrates without further treatment were injected into the HPLC-system via 
an autosampler in appropriate volume.  
 
2.5.3. Preparation of standard solutions 
A solution containing 500 g/ml of each analyte was prepared and diluted to contain 500 
ng/ml of each component. Finally, to plot the standard curve three different analytes' 
concentrations were used: 20 ng/ml, 40 ng/ml, 80 ng/ml. 
 
2.5.4. Instrumentation and Chromatographic Conditions 
The concentrations of NA, MHPG, DA, DOPAC, HVA, 5-HT and HIAA were determined 
using HPLC-ED. The HPLC system was an Agilent Technologies 1100 chromatograph 
coupled to an electrochemical detector (model 1640, Bio-Rad, Munich, Germany) equipped 
with a glassy carbon working electrode and an Ag/AgCl reference electrode. On the day of 
analysis, samples were allowed to thaw, placed in the autosampler and kept at + 15 º C before 
injection. Varying injection volumes were used, however the standard injection volume per 
sample was 50 µl. Calculation of the analytes' concentrations in samples was performed 
relating the injection volume of the sample to that of the external standard. The separation 
column was EC 250/4.6 NUCLEOSIL
®
100-5 C18 (Macherey-Nagel, Düren, Germany) and it 
was thermostated to 35 º C.  
A stock solution (SS) for the mobile phases was prepared: 1 mol/L NaH2PO4, 1 mmol/L 
EDTA, 6.5 mmol/L OSA, 5 mmol/L TEA, in highly purified water. From the SS mobile 
phases A (10 % SS + 90 % H2O) and B (10 % SS + 40 % H2O + 50 % MeOH) were prepared. 
Mobile phases were adjusted to pH 4 using H3PO4. The eluent flow rate was set to 0.8 
ml/min. The method is based on a previously published one using isocratic elution [39]. A 
binary HPLC-pump was used for gradient elution. The starting composition of the mobile 
phase was 88 % A and 12 % B and was kept for 10 min. During the following 20 min gradual 
adjustement to 30 % A and 70 % B was performed and this percentage kept for 10 min. For 
column reequilibration, percentages of A and B were returned to initial conditions within 4 
min and kept for 6 min before the next sample injection. Total acquisition time was 50 min 
per sample. Analytes were detected applying an oxidation potential of 0.72 V versus the 
reference electrode. Chromatograms were acquired with Agilent ChemStation for LC 3D 
software.  
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2.5.5. Quantification, validation and statistical analysis 
The calibration standards for the quantification validation contained NA, MHPG, DA, 
DOPAC, HVA, 5-HT and 5-HIAA. Calibration plots were generated by plotting the peak 
height versus the standards' solution concentration (20 ng/ml, 40 ng/ml, 80 ng/ml). Analyte 
concentrations in biological samples were finally expressed as ng/g of brain tissue. The 
retention times were the following: 5.8 min for NA, 12.6 min for DA, 14.3 min for MHPG, 
20.9 min for DOPAC, 24.0 min for 5-HT, 26.7 min for 5-HIAA and 30.2 min for HVA.  
The limit of detection (LOD) was 1.3 ng/ml for NA, MHPG, DA as well as for DOPAC and 
2.5 ng/ml for 5-HT, 5-HIAA as well as for HVA.  
The results are presented as mean ± standard error mean (SEM). ANOVA test was conducted 
and between-group differences were analyzed by Newman–Keuls post hoc test. P < 0.05 was 
considered significant. 
 
RESULTS 
 
Similarly to previous experiments [28], BTX-A peripheral injection into the whisker pad 
reduced the duration of second phase of the nocifensive behavior induced by orofacial 
formalin in rats (saline + formalin treatment = 457± 40 seconds; BTX-A + formalin treatment 
= 310 ± 27 seconds, p<0.01 (two-tailed unpaired t-test)). In amygdala and trigeminal nucleus 
caudalis (TNC), formalin induced pain caused a statistically significant rise of HVA and 
DOPAC, respectively, however the BTX-A effect remained insignificant. In hypothalamus, 
the 5-HT levels were higher in rats treated with BTX-A (BTX-A + saline) compared to the 
control (saline + saline) group. In brain regions related to nociceptive transmission we did not 
observe statistically significant changes of monoamines or their metabolites after formalin 
induced pain and BTX-A administration. In all the remaining brain regions BTX-A has not 
caused significantly different changes of monoamines or their metabolites, except for striatum 
where BTX-A increased NA concentrations. All results are presented in Table 1.  
 
DISCUSSION AND CONCLUSION 
 
The natural target of BTX is represented by the neuromuscular junction, where BTX 
poisoning results in flaccid paralysis due to blockade of acetylcholine release [6]. Beside the 
peripheral effects, BTX-A is known for its central effects, too. Studies in rodents show that 
the toxin is retrogradely transported and transcytosed to second-order neurons in the central 
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nervous system [2, 3, 37]. Also, studies in humans support the idea that BTX-A injected at 
therapeutic doses induces distant spinal and cortical effects indirectly by promoting brain 
changes due to plastic rearrangements subsequent to denervation or alterations in sensory 
input [22]. An excellent clinical example is that BTX injected into the affected muscles in 
patients with cervical dystonia relieves pain [10]. In addition, possible direct central actions 
mediated through toxin axonal transport from periphery to the spinal cord ventral horn have 
been reported in patients treated for spasticity [26]. In the present study we examined the 
effects of BTX-A on concentrations of neurotransmitters and their metabolites in brain 
regions involved in pain transmission and processing, as well as motor regions considering 
that BTX-A is reaching the facial nucleus and trigeminal nucleus caudalis via motor and 
sensory neurons, respectively [2, 28]. Results showed that BTX-A did not cause a significant 
change in concentrations of monoamines and their metabolites in a model of formalin induced 
pain with the exception of DOPAC in the trigeminal nucleus caudalis and for HVA in the 
amygdala. Therefore, it would be reasonable to conclude that in this model the BTX-A 
antinociceptive effect is not related to central monoamines. Interestingly, in two brain regions 
we observed low but significant changes in monoamine concentrations in saline + BTX-A-
treated animals. BTX-A caused a bilateral increase of 5-HT in hypothalamus and an 
ipsilateral increase of NA in striatum. These data would require further confirmation and 
elaboration through experimental work, however the current results and  rise in 5-HT and NA 
concentrations may be useful in explaining the role of BTX-A in depression or  depression 
associated pain [15] and sleep [19,12]. Biochemical and pharmacological studies have 
demonstrated that changes in neurotransmitter concentrations play an important role in the 
pathogenesis of depression [9, 41, 38]. The monoamine hypothesis postulates that depletion in 
the levels of 5-HT, NA, and/or DA in the CNS are the pathophysiologic basis of depression 
[1]. 5-HT, NA and DA are involved in mood regulation and states such as sleep, anxiety, 
alertness, attention and reward processes. The purpose of major antidepressant drug types is to 
enhance and prolong the action of NA and/or 5-HT and/or DA. That is achieved by various 
mechanisms including altering the reuptake, degradation or receptor pharmacodynamics of 
biogenic amines [21] or even influencing gene expression, synaptic plasticity, neurogenesis, 
and neuronal survival [23, 47]. Our experiment has shown that BTX-A caused a rise in 5-HT 
in hypothalamus, which is along with other limbic system regions investigated here 
(amygdala, thalamus and hippocampus) a brain region that plays a significant role in 
depression. Similarly, BTX-A peripheral injection has also raised the NA concentrations in 
striatum, a region implicated rather in retarded depression. Our previous experiments 
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suggested that BoNT/A enzymatic activity is not detectable in higher order brain regions 
projecting to trigeminal nucleus caudalis, however, it may affect pain-evoked neuronal 
activation in regions where its enzymatic activity is not detectable (locus coeruleus and 
periaqueductal gray) [28]. Similarly, BTX-A mediated up-regulation of serotonin and 
noradrenaline concentrations in hypothalamus and striatum probably results from indirect 
modulation of neural activity within distant brain regions rather than the direct BTX-A action. 
Our results may also be interpreted as to support the hypothesis of recent studies that 
associated BTX-A with significant improvement in depressive symptoms [14, 24, 25]. 
Converging lines of evidence suggested a role for facial expressions in the pathophysiology 
and treatment of mood disorders [14]. Finzi and Wasserman  were the first to report cases of 
depression treated with BTX-A [15]. The studies that followed [18, 32, 13, 49, 16, 45, 46, 20, 
17, 14, 29, 25] were also based on the facial feedback hypothesis and designed to evaluate 
antidepressant effects after injecting BTX-A into the corrugator and procerus muscles of the 
glabellar region. The hypothesis implies that the brain continuously assesses the extent of 
facial muscle contraction and muscle tension by proprioception. One can view the state of 
corrugator muscle tension as part of a neuronal circuit involving the brainstem, with motor 
input from the facial nerve and sensory afferents from facial and trigeminal cranial nerves. 
BTX-A treatment of the corrugator muscle, would interrupt the normal circuitry, reduce 
distress signals to the brain and thereby influence mood in a favorable way [14]. The 
interruption of this feedback loop by the paralysis of the respective muscles is caused by 
reversible inhibition of acetylcholine release. Some of the benefits of BTX-A as an 
antidepressant agent is that it is not absorbed systematically, the long-lasting effect of a single 
dose and the limited adverse reactions. As binding of [3H]-imipramine and [3H]-serotonin do 
not change after tetanus toxin as well as BTX-A in isolated brain synaptosomes, this indicates 
that these Clostridium neurotoxins do not act on the serotonin high-affinity site at SERT or at 
other serotonin high affinity sites [31]. Indeed, evidence suggest that the SNARE protein 
syntaxin 1A binds to the N-terminal tail of SERT thus regulating SERT-conducting states 
including cell excitability and drug mediated effects [35, 34]. Effects of BTX-C,D 
demonstrate inhibitory effects on 5-HT1C receptor induced Cl-current in Xenopus oocytes 
[42]. In addition, low molecule weightG-proteins ADP-ribosylated by botulinum ADP-
ribosyltransferaseare involved in phospholipase C activity [43]. Serotonin facilitates AMPA-
type responses in isolated siphon motor neurons of Aplysia in culture [8]. Therefore, even if 
there are only mild changes in concentrations of biogenic amines and their metabolites, this 
does not rule out BTX-induced changes in transmitter responses. Syntaxin 1A also regulates 
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DA transporter activity, phosphorylation and surface expression [7] and SNARE proteins are 
involved in exocytosis of NA from synaptic vesicles at low frequencies of stimulation [30, 4] . 
It is evident that proteolysis of SNARE proteins alters facilitation and depression in a specific 
way [48, 50]. By this, changes in neurotransmission by BTX may be able to influence clinical 
phenotypes like depression, sleep and pain. Further studies are required to elucidate the role 
of the elevated brain concentrations of 5-HT and NA observed after BTX-A facial injection in 
our study and to elucidate the inhibitory effect of BTX-A on peripheral acetylcholine release, 
which also might contribute to antidepressant BTX-A activity. 
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TABLE  
 
 
Brain regions with significant changes in concentrations of biogenic amines and /or their 
metabolites.  
 
BIOGENIC AMINE 
/ METABOLITE 
REGION TREATMENT GROUPS p 
NA Striatum (ipsi) BTX-A + saline ipsi vs. saline + saline ipsi p < 0.01 
5-HT Hypothalamus (ipsi) BTX-A + saline ipsi vs. saline + saline ipsi p < 0.05 
DOPAC Trigeminal nucleus caudalis (contra) saline + formalin cont vs. saline + formalin ipsi p < 0.05 
HVA Amygdala (contra) saline + formalin cont vs. saline + formalin ipsi p < 0.05 
 
